Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2815-2822

  Rustin, Gordon J S ^a   Galbraith, Susan M ^a   Anderson, Helen ^a   Stratford, Michael ^a   Folkes, Lisa K ^a   Sena, Luiza ^a   Gumbrell, Lindsey ^a   Price, Patricia M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; GLUCURONIDE; ANTINEOPLASTIC AGENT; BIBENZYL DERIVATIVE; COMBRETASTATIN; STILBENE DERIVATIVE;

ADRENAL CORTEX CARCINOMA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG METABOLISM; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HUMAN; HYPERTENSION; HYPOTENSION; INTESTINE ISCHEMIA; LIVER METASTASIS; LYMPHOCYTOPENIA; MOTOR NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SYNCOPE; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VISUAL DISORDER; VOMITING; ADULT; AGED; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ADMINISTRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFUSION PUMP; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIBENZYLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSION PUMPS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; STATISTICS, NONPARAMETRIC; STILBENES; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0042386700     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.185     Document Type: Article

References (26)

1. Pettit GR, Cragg GM, Herald DL, et al: Isolation and structure of combretastatin. Can J Chem 60:1374-1376, 1982
2. Pettit GR, Singh SB, Hamel E, et al: Isolation and structure of the strong growth and tubulin inhibitor combretastatin A-4. Experentia 45:209-211, 1989
3. Pettit GR, Temple C Jr, Narayanan VL, et al: Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299-309, 1995
4. Hamel E, Lin CM: Interactions of combretastatin, a new plant-derived anti-mitotic agent, with tubulin. Biochem Pharmacol 32:3864-3867, 1983
5. Chaplin DJ, Pettit GR, Parkins CS, et al: Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer 74:S86-S88, 1996
6. Dark GG, Hill SA, Prise VE, et al: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57:1829-1834, 1997
7. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195, 1999
8. Pedley R, Hill S, Boxer G, et al: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 61:4716-4722, 2001
9. Tozer GM, Prise VE, Wilson J, et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 59:1626-1634, 1999
10. Grosios K, Holwell SE, McGown AT, et al: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318-1327, 1999
11. Watts ME, Woodcock M, Arnold S, et al: Effects of novel and conventional anti-cancer agents on human endothelial permeability: Influence of tumour secreted factors. Anticancer Res 17:71-75, 1997
12. Galbraith SM, Chaplin DJ, Lee F, et al: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21:93-102, 2001
13. Dowlati A, Robertson K, Cooney M, et al: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416, 2002
14. Stevenson JP, Gallagher M, Sun W, et al: Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily x 5 schedule every 21 days. Proceedings of the 91 St annual meeting of the Am Assoc Cancer Res 2000:3469
15. Galbraith SM, Maxwell RJ, Lodge MA: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831-2842, 2003
16. Anderson HL, Yap JT, Miller MP: Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:2823-2830, 2003
17. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
18. Stratford MR, Dennis MF: Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 721:77-85, 1999
19. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
20. Zhu Z, Witte L: Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 17:195-212, 1999
21. Kakolyris S, Fox S, Koukourakis M, et al: Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 82:844-851, 2000
22. Denekamp J: The current status of targeting tumour vasculature as a means of cancer therapy: An overview. Int J Radiat Biol 60:401-408, 1991
23. Bloemendal H, Logtenberg T, Voest E: New strategies in antivascular cancer therapy. Eur J Clin Invest 29:802-809, 1999
24. Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136-139, 1982
25. Grosios K, Loadman PM, Swaine DJ, et al: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20:229-233, 2000
26. Li L, Rojiani A, Siemann D: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys 42:899-903, 1998